SAN DIEGO, Sept. 13 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL - News) announced today the issuance of U.S. Patent No. 7,105,574 covering both the novel Vaxfectin(TM) adjuvant and its use with conventional vaccines against infectious diseases and cancer. The company holds previously issued patents in the United States and Europe covering the use of Vaxfectin(TM) with DNA vaccines.
